The “Best of Antiangiogenesis” is a series of webcasts, generated through Project ENABLE™, featuring presentations from leading medical experts describing research and perspectives on new angiogenesis-based therapies
These webcast presentations are derived from the Angiogenesis Foundation’s 10th Annual M. Judah Folkman Antiangiogenesis Conference, held October 6-7, 2012 in Cambridge, Massachusetts.
The presentations were originally intended for a professional audience so may be technical in content. The information contained in these webcasts is in no way meant to substitute for medical care.
Annette T. Byrne, B.Sc. (Hons), Ph.D.
Royal College of Surgeons in Ireland
Michael Retsky, Ph.D.
Harvard School of Public Health
Lauren C. Harshman, M.D.
Dana-Farber Cancer Institute
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Angiogenesis Foundation’s Policies.
PROGRAMS AND FACULTY
AngioPredict: predicting response to therapy in metastatic colorectal cancer
Annette T. Byrne, B.Sc. (Hons), Ph.D.
Royal College of Surgeons in Ireland
Inflammatory markers for cancer recurrence
Michael Retsky, Ph.D.
Harvard School of Public Health
Conditional survival analysis in renal cell carcinoma treated with targeted therapies
Lauren C. Harshman, M.D.
Dana-Farber Cancer Institute
HEALTHCARE GAP
Even with approved agents on the market, antiangiogenic therapy represents a relatively new approach to cancer management, which leads to a critical need to rapidly and effectively educate physicians about: the scientific and clinical rationale for treating tumor angiogenesis; the pathways and mechanisms involved in tumor angiogenesis; the strategies by which antiangiogenic agents are being integrated into traditional therapeutic protocols; the efficacy and safety data emerging from well-designed and rigorous clinical studies of antiangiogenic therapy; and how this data can directly be used to improve clinical decision-making and outcomes for cancer patients. In addition, many clinicians were trained before the era of targeted therapies and can be overwhelmed with the intricacies of signal pathways, their interrelationships, and the effects of therapies. Therefore, there is an opportunity to educate clinicians about this complex information using visual graphic communication tools.
PROGRAM LEARNING OBJECTIVES
At the conclusion of this educational activity, you will be able to:
- Summarize angiogenesis-based targets for treating angiogenesis-dependent diseases that improve patient outcomes
- Discuss recent clinical data supporting the use of emerging and approved angiogenesis-based treatments that benefit patients and their advocates
- Interpret safety and efficacy data from advanced and pivotal clinical trials of angiogenesis-based therapies
- Describe and differentiate new strategies integrating angiogenesis agents with current therapies